サイクリン依存キナーゼ4 / 6阻害剤リボシクリブ誘発大腸炎で,パルボシクリブへの成功移行
Ishitha Jagadish1, Phoebe Newell1, Hung Thieu Khong2
1Internal Medicine, Banner - University Medical Center Phoenix, Phoenix, Arizona, USA.
BMJ case reports
|August 21, 2025
まとめ
サイクリン依存キナーゼ4/6阻害剤 (CDK4/ 6Is) は珍しい大腸炎を引き起こす可能性があります. このケースは,転移性乳がん患者のこのような薬剤副作用の特定と管理のための市場公開後の監視の重要性を強調しています.
科学分野:
- 腫瘍学
- 薬理学について
- 胃腸内科
背景:
- ホルモン受容体陽性 (HR+) とヒト表皮成長因子受容体2陰性転移性乳がんは,内分泌療法とCDK4/ 6阻害剤 (CDK4/ 6I) で治療されます.
- リボシクリブ誘発性大腸炎は,発生頻度が不十分で,公表データも限られている稀な副作用です.
- 薬剤誘発性大腸炎の早期発見と治療は,患者のアウトカムにとって極めて重要です.
研究 の 目的:
- 転移性乳がん患者のリボシクリブ誘発性大腸炎を報告する.
- リボシクリブ誘発大腸炎の成功管理について説明します.
- 薬物の販売後に発生する 希少な有害事象に対する監視の重要性を強調する.
主な方法:
- レトロゾールとリボシクリブで治療された転移性HR+乳がん患者のケース研究.
- 急性下痢の臨床表現と 腸内炎の放射線検査結果
- 治療には,リボシクリブを中止し,ステロイド治療を行い,その後,パルボシクリブに切り替えることが含まれていた.
主要な成果:
- 患者さんはリボシクリブ投与開始後,急性下痢を発症し,パンコーライトと診断されました.
- リボシクリブとコルチコステロイドの治療を中止すると,大腸炎は治りました.
- 患者さんは他のCDK4/ 6阻害剤であるパルボシクリブを許容し,大腸炎は再発しなかった.
結論:
- リボシクリブは大腸炎を誘発することがあり,これは珍しいが深刻な副作用です.
- がん治療の希少な副作用を検出し,管理するために,市場公開後の薬物監視は不可欠です.
- CDK4/ 6阻害剤による大腸炎の比較リスクとリスク因子に関するさらなる調査が必要である.
関連する概念動画
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
01:30Inflammatory Bowel Disease II: Crohn's Disease
382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382